Christian Seufert, President, Capsules & Health Ingredients, Lonza, commented: “The Innovaform™ Innovation and Formulation Accelerator represents a unique solution for drug developers seeking to solve complex dosage form and delivery challenges through innovation.

Under the terms of the agreement, Novo Nordisk and NanoVation Therapeutics will collaborate on two lead programs to develop base-editing therapies for certain rare genetic diseases, and up to five additional future targets for cardiometabolic and rare diseases.

MindLight is the first circular RNA biomarker-based assay designed to predict whether a patient with depression, also known as major depressive disorder, will respond to selective serotonin reuptake inhibitor (SSRI) antidepressant treatment.

This session, entitled, “Transforming Clinical Trials: From Reactive to Predictive,” takes place during the DPHARM Innovative Collaborations Track C, on Tuesday, September 17, 2024, at 4:10pm EDT reports Edetek.

“We are thrilled to obtain the CE mark for our MosaiQ AiPlex CD microarray,” said Manuel O. Mendez, CEO of AliveDx. “The MosaiQ fast portfolio expansion marks our fourth microarray CE mark approval in the last 12 months reflecting our dedication to rapidly advance diagnostic technologies and our commitment to support the millions of individuals affected by autoimmune diseases. Early and accurate diagnosis is crucial for managing this condition. Our innovative MosaiQ microarray solutions represent a significant advancement to partner with laboratorians and clinicians to reduce healthcare costs and improve patient outcomes and quality of life.”